Which has better earnings & valuation, GILD or AMGN?

Gilead Sciences has higher earnings, but lower revenue than Amgen. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gilead Sciences $29.44B 5.45 $8.51B $7.34 17.62 Amgen $36.75B 5.52 $7.71B $14.37 26.17

Is GILD or AMGN more profitable?

Gilead Sciences has a net margin of 30.99% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Gilead Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences 30.99% 48.19% 18.28% Amgen 20.96% 137.41% 13.28%

Does the media prefer GILD or AMGN?

In the previous week, Gilead Sciences had 5 more articles in the media than Amgen. MarketBeat recorded 43 mentions for Gilead Sciences and 38 mentions for Amgen. Amgen's average media sentiment score of 1.27 beat Gilead Sciences' score of 1.04 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 29 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 29 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LGND or GILD?

In the previous week, Gilead Sciences had 32 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 43 mentions for Gilead Sciences and 11 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.07 beat Gilead Sciences' score of 1.04 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 29 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, MRNA or GILD?

Gilead Sciences has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 11.04 -$2.82B -$8.15 N/A Gilead Sciences $29.44B 5.45 $8.51B $7.34 17.62

Is MRNA or GILD more profitable?

Gilead Sciences has a net margin of 30.99% compared to Moderna's net margin of -143.55%. Gilead Sciences' return on equity of 48.19% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Gilead Sciences 30.99% 48.19% 18.28%

Does the media refer more to MRNA or GILD?

In the previous week, Gilead Sciences had 28 more articles in the media than Moderna. MarketBeat recorded 43 mentions for Gilead Sciences and 15 mentions for Moderna. Gilead Sciences' average media sentiment score of 1.04 beat Moderna's score of 0.60 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Gilead Sciences 29 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to REGN or GILD?

In the previous week, Regeneron Pharmaceuticals had 18 more articles in the media than Gilead Sciences. MarketBeat recorded 61 mentions for Regeneron Pharmaceuticals and 43 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.04 beat Regeneron Pharmaceuticals' score of 0.69 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 26 Very Positive mention(s) 4 Positive mention(s) 26 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Gilead Sciences 29 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VIR or GILD?

In the previous week, Gilead Sciences had 37 more articles in the media than Vir Biotechnology. MarketBeat recorded 43 mentions for Gilead Sciences and 6 mentions for Vir Biotechnology. Gilead Sciences' average media sentiment score of 1.04 beat Vir Biotechnology's score of 0.67 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 29 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Gilead Sciences (GILD) Competitors

$129.31 -1.55 (-1.18%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$130.46 +1.15 (+0.89%)

As of 07/24/2026 07:34 PM Eastern

Compare

GILD vs. AMGN, LGND, MRNA, REGN, and VIR

Should you buy Gilead Sciences stock or one of its competitors? MarketBeat compares Gilead Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gilead Sciences include Amgen (AMGN), Ligand Pharmaceuticals (LGND), Moderna (MRNA), Regeneron Pharmaceuticals (REGN), and Vir Biotechnology (VIR). These companies are all part of the "med - biomed/gene" industry.

How does Gilead Sciences compare to Amgen?

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Gilead Sciences has higher earnings, but lower revenue than Amgen. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.45	$8.51B	$7.34	17.62
Amgen	$36.75B	5.52	$7.71B	$14.37	26.17

Gilead Sciences has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.7%. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Amgen pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 10 consecutive years and Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Gilead Sciences had 5 more articles in the media than Amgen. MarketBeat recorded 43 mentions for Gilead Sciences and 38 mentions for Amgen. Amgen's average media sentiment score of 1.27 beat Gilead Sciences' score of 1.04 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	29 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	29 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Gilead Sciences has a net margin of 30.99% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Amgen	20.96%	137.41%	13.28%

Gilead Sciences currently has a consensus price target of $158.33, indicating a potential upside of 22.44%. Amgen has a consensus price target of $356.62, indicating a potential downside of 5.17%. Given Gilead Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Gilead Sciences is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by insiders. Comparatively, 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Amgen beats Gilead Sciences on 11 of the 20 factors compared between the two stocks.

How does Gilead Sciences compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Gilead Sciences had 32 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 43 mentions for Gilead Sciences and 11 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.07 beat Gilead Sciences' score of 1.04 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	29 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 55.95% compared to Gilead Sciences' net margin of 30.99%. Gilead Sciences' return on equity of 48.19% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
Gilead Sciences	30.99%	48.19%	18.28%

Ligand Pharmaceuticals has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Ligand Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	22.46	$124.45M	$7.37	40.78
Gilead Sciences	$29.44B	5.45	$8.51B	$7.34	17.62

Ligand Pharmaceuticals presently has a consensus price target of $319.00, indicating a potential upside of 6.15%. Gilead Sciences has a consensus price target of $158.33, indicating a potential upside of 22.44%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Ligand Pharmaceuticals beats Gilead Sciences on 9 of the 16 factors compared between the two stocks.

How does Gilead Sciences compare to Moderna?

Moderna (NASDAQ:MRNA) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

In the previous week, Gilead Sciences had 28 more articles in the media than Moderna. MarketBeat recorded 43 mentions for Gilead Sciences and 15 mentions for Moderna. Gilead Sciences' average media sentiment score of 1.04 beat Moderna's score of 0.60 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Gilead Sciences	29 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

75.3% of Moderna shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Gilead Sciences has a net margin of 30.99% compared to Moderna's net margin of -143.55%. Gilead Sciences' return on equity of 48.19% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Gilead Sciences	30.99%	48.19%	18.28%

Moderna currently has a consensus price target of $40.00, suggesting a potential downside of 26.02%. Gilead Sciences has a consensus price target of $158.33, suggesting a potential upside of 22.44%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

Moderna has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	11.04	-$2.82B	-$8.15	N/A
Gilead Sciences	$29.44B	5.45	$8.51B	$7.34	17.62

Summary

Gilead Sciences beats Moderna on 13 of the 16 factors compared between the two stocks.

How does Gilead Sciences compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Regeneron Pharmaceuticals presently has a consensus price target of $787.88, suggesting a potential upside of 20.10%. Gilead Sciences has a consensus price target of $158.33, suggesting a potential upside of 22.44%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

Gilead Sciences has a net margin of 30.99% compared to Regeneron Pharmaceuticals' net margin of 29.65%. Gilead Sciences' return on equity of 48.19% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Gilead Sciences	30.99%	48.19%	18.28%

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	4.84	$4.50B	$41.04	15.98
Gilead Sciences	$29.44B	5.45	$8.51B	$7.34	17.62

Regeneron Pharmaceuticals has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.6%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Regeneron Pharmaceuticals pays out 9.2% of its earnings in the form of a dividend. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Regeneron Pharmaceuticals had 18 more articles in the media than Gilead Sciences. MarketBeat recorded 61 mentions for Regeneron Pharmaceuticals and 43 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.04 beat Regeneron Pharmaceuticals' score of 0.69 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	26 Very Positive mention(s)	4 Positive mention(s)	26 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Gilead Sciences	29 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Gilead Sciences beats Regeneron Pharmaceuticals on 15 of the 20 factors compared between the two stocks.

How does Gilead Sciences compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Gilead Sciences had 37 more articles in the media than Vir Biotechnology. MarketBeat recorded 43 mentions for Gilead Sciences and 6 mentions for Vir Biotechnology. Gilead Sciences' average media sentiment score of 1.04 beat Vir Biotechnology's score of 0.67 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	29 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vir Biotechnology presently has a consensus price target of $20.88, suggesting a potential upside of 140.22%. Gilead Sciences has a consensus price target of $158.33, suggesting a potential upside of 22.44%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

Gilead Sciences has a net margin of 30.99% compared to Vir Biotechnology's net margin of -638.88%. Gilead Sciences' return on equity of 48.19% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Gilead Sciences	30.99%	48.19%	18.28%

Gilead Sciences has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	21.38	-$437.99M	-$3.13	N/A
Gilead Sciences	$29.44B	5.45	$8.51B	$7.34	17.62

Vir Biotechnology has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Summary

Gilead Sciences beats Vir Biotechnology on 11 of the 17 factors compared between the two stocks.

Get Gilead Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GILD vs. The Competition

Export

Metric	Gilead Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$160.55B	$3.67B	$7.06B	$12.20B
Dividend Yield	2.54%	2.19%	2.67%	9.41%
P/E Ratio	17.62	21.29	27.14	23.63
Price / Sales	5.45	297.82	582.30	111.98
Price / Cash	12.35	153.89	49.81	58.78
Price / Book	7.09	7.88	10.28	6.01
Net Income	$8.51B	$23.86M	$3.60B	$331.99M
7 Day Performance	-3.70%	-3.82%	-1.27%	-0.63%
1 Month Performance	1.13%	-4.45%	-1.67%	-3.04%
1 Year Performance	11.28%	33.01%	18.25%	13.30%

Gilead Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GILD Gilead Sciences	4.9207 of 5 stars	$129.31 -1.2%	$158.33 +22.4%	+11.3%	$160.55B	$29.44B	17.62	17,000	News Coverage Positive News Analyst Downgrade
AMGN Amgen	4.0401 of 5 stars	$364.17 -0.6%	$356.62 -2.1%	+22.7%	$196.55B	$37.22B	25.34	31,500	Positive News
LGND Ligand Pharmaceuticals	4.0147 of 5 stars	$293.99 -3.1%	$304.00 +3.4%	+121.3%	$5.89B	$268.09M	39.89	80	News Coverage Positive News Analyst Forecast
MRNA Moderna	1.5981 of 5 stars	$59.49 -3.8%	$38.80 -34.8%	+58.3%	$23.61B	$1.94B	N/A	4,700	Upcoming Earnings Analyst Forecast
REGN Regeneron Pharmaceuticals	4.4555 of 5 stars	$672.15 -0.7%	$787.67 +17.2%	+16.5%	$71.06B	$14.34B	16.38	15,410	Trending News Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GILD) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gilead Sciences (GILD) Competitors

GILD vs. AMGN, LGND, MRNA, REGN, and VIR

How does Gilead Sciences compare to Amgen?

Summary

How does Gilead Sciences compare to Ligand Pharmaceuticals?

Summary

How does Gilead Sciences compare to Moderna?

Summary

How does Gilead Sciences compare to Regeneron Pharmaceuticals?

Summary

How does Gilead Sciences compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD vs. The Competition

Gilead Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gilead Sciences (GILD) Competitors

GILD vs. AMGN, LGND, MRNA, REGN, and VIR

How does Gilead Sciences compare to Amgen?

Which has better earnings & valuation, GILD or AMGN?

Which has more volatility & risk, GILD or AMGN?

Is GILD or AMGN a better dividend stock?

Does the media prefer GILD or AMGN?

Is GILD or AMGN more profitable?

Do analysts recommend GILD or AMGN?

Do insiders & institutionals believe in GILD or AMGN?

Summary

How does Gilead Sciences compare to Ligand Pharmaceuticals?

Do insiders and institutionals believe in LGND or GILD?

Does the media favor LGND or GILD?

Is LGND or GILD more profitable?

Which has more risk and volatility, LGND or GILD?

Which has preferable valuation & earnings, LGND or GILD?

Do analysts rate LGND or GILD?

Summary

How does Gilead Sciences compare to Moderna?

Does the media refer more to MRNA or GILD?

Do insiders and institutionals hold more shares of MRNA or GILD?

Is MRNA or GILD more profitable?

Do analysts recommend MRNA or GILD?

Which has more risk and volatility, MRNA or GILD?

Which has higher earnings and valuation, MRNA or GILD?

Summary

How does Gilead Sciences compare to Regeneron Pharmaceuticals?

Do analysts recommend REGN or GILD?

Is REGN or GILD more profitable?

Which has preferable earnings & valuation, REGN or GILD?

Which has more risk & volatility, REGN or GILD?

Is REGN or GILD a better dividend stock?

Do insiders & institutionals have more ownership in REGN or GILD?

Does the media refer more to REGN or GILD?

Summary

How does Gilead Sciences compare to Vir Biotechnology?

Does the media favor VIR or GILD?

Do institutionals and insiders hold more shares of VIR or GILD?

Do analysts rate VIR or GILD?

Is VIR or GILD more profitable?

Which has higher valuation & earnings, VIR or GILD?

Which has more volatility & risk, VIR or GILD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD vs. The Competition

Gilead Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools